The biggest difference is that tirzepatide targets two hormone pathways while retatrutide targets three
Retatrutide : Phase 2 completed for obesity (NEJM 2023, 338 patients) and Phase 2a for MASH
Food and Drug Administration (FDA) in 2011
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
Future studies will focus on long-term efficacy, safety, and the feasibility of oral administration
Sulfur Burps on GLP-1 Medications: Causes, Fixes, and When to Worry At a glance Cause / slowed gastric emptying from GLP-1 receptor activation leads to bacterial fermentation of sulfur foods Peak timing / most intense during weeks 1-12 on semaglutide
